Adial Pharmaceuticals, Inc. (ADIL)
NCM · Healthcare · Biotechnology
$4.90
-18.33%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$14.4M
Shares Outstanding
2.9M
Exchange
NCM
Currency
USD
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.8M) | (1.9M) | (2.0M) | (52.0M) |
| Net Income | (1.8M) | (2.0M) | (2.0M) | (52.0M) |
| Diluted EPS | $-2.00 | N/A | $-1.48 | $-11.25 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (10.9M) | (6.9M) | (8.3M) | (7.8M) |
| Net Income | (12.7M) | (5.1M) | (13.2M) | (8.0M) |
| Diluted EPS | $-317.75 | $-90.00 | $-68.01 | $-11.93 |